Expanded Access to Navitoclax

Study Identifier
C19-199
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

Study Details

Medical Condition
  • Blood Cancer - Other
  • Blood Cancer - Leukemia (Other)
  • Blood Cancer - Lymphoma (General)
  • Study Drug
  • Navitoclax
  • Venetoclax
  • Phase
    N/A
    Sex
    N/A
    Age
    4+ years

    Protocol Summary

    This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to navitoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

    Study Locations

    No locations found.